Context Therapeutics Inc. announced on June 2, 2025, that it is presenting a Trial in Progress poster for the Phase 1 clinical trial evaluating CTIM-76 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting was held from May 30 – June 3, 2025, in Chicago, IL.
The poster provides an update on the Phase 1 clinical trial of CTIM-76, a Claudin 6 x CD3 T cell engager, which is being evaluated in ovarian, endometrial, and testicular cancers. The company is currently dosing cohort 3 of the Phase 1 trial.
The Phase 1 study is an open-label, dose escalation and expansion trial designed to assess the safety, tolerability, pharmacokinetics, and anti-tumor activity of CTIM-76. Context expects to share initial data from this trial in the first half of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.